The Ministry is responsible for formulating and conducting the national industrial policy, fostering research and technological development, exports and business, coordinating a common energetic and trade policy within the European Common Market. It also promotes small and medium-size companies and oversights the protection of consumers.
Corvallis Microfluidics Tech Hub
The Corvallis Microfluidics Tech Hub (CorMic) is a public-private consortium aimed at accelerating the commercialization and scale of start-ups and small companies developing microfluidics-based products for biotechnology, advanced chip cooling, and new chemical synthesis through continuous flow processing. We will support companies with unique facilities and services in the Willamette Valley region of Oregon, with our main Foundry+ facilities in Corvallis, Oregon. The Foundry+ will include a user-accessible silicon microfluidics prototyping fab on the HP Inc Corvallis campus, with support for chip design, manufacturing and analysis from HP technical subject matter experts. The facilities will also include user-accessible biotech and continuous flow processing space with capital-intensive shared equipment and private, dedicated incubation spaces for company product development. CorMic end-users will benefit from support ranging from venture access to accelerator services to business planning services from the extensive CorMic consortium. Additionally, CorMic end-users will be part of a welcoming start-up ecosystem in Oregon, where companies lift each other up and celebrate success.
Connecticut Pavilion
Successful companies pick the best location for their business, but transformative companies pick the best location for their people. The success of your business is determined by the quality of your workforce and their ability to adapt to new technologies fueled by innovation. In Connecticut, we’re investing in our people to ensure that everyone has the opportunity to grow their skills, adapt to new technologies and thrive. Whether it’s in K-12 education, in world-class universities such as Yale and the University of Connecticut, or through our workforce development and training programs, we’re investing in the future and removing barriers to success. Innovation isn’t just a word in Connecticut, it is a way of life that’s open to everyone. | The Department of Economic and Community Development is Connecticut’s lead agency responsible for strengthening the state’s competitive position in the rapidly changing, knowledge-based global economy. The agency takes a comprehensive approach to economic development that incorporates community development, transportation, education, and arts and culture. Specifically, the department: Supports existing businesses and attracts new businesses and jobs with a wide range of programs and services to help companies prosper; promotes Connecticut industries and businesses here at home, throughout the country and across the globe; strengthens Connecticut’s communities by providing funding and technical support for local community and economic development projects; works to make tourism a leading economic contributor and a source of pride for Connecticut; develops and strengthens the arts in Connecticut and makes artistic experiences widely available to residents and visitors; and helps to eliminate brownfield properties by promoting smart growth principles, strengthening public/private partnerships and providing a one-stop resource for expertise. | Connecticut is a powerhouse in bioscience, life sciences, and biotechnology, standing at the forefront of groundbreaking medical advancements, cutting-edge research, and transformative discoveries. Strategically located in the Northeast corridor, between the major biotech hubs of Boston and New York City, Connecticut offers a thriving ecosystem for companies, researchers, and investors looking to shape the future of healthcare and scientific innovation. A Thriving Bioscience Ecosystem Connecticut is home to more than 1,300 bioscience and life science companies, including globally recognized leaders such as Pfizer, Boehringer Ingelheim, Alexion Pharmaceuticals (AstraZeneca Rare Disease), and Medtronic. These companies, along with a network of startups, incubators, and research institutions, are driving advancements in precision medicine, genomics, biopharmaceuticals, digital health, and medical devices. The state’s bioscience sector benefits from a deep talent pool, nurtured by world-class universities, including Yale University and the University of Connecticut, which are renowned for their research in genomics, drug discovery, immunology, and bioengineering. With access to top-tier researchers, state-of-the-art facilities, and robust funding opportunities, Connecticut is a prime destination for companies at all stages of growth. Cutting-Edge Research & Innovation Connecticut boasts a dynamic research environment supported by renowned institutions such as the Yale School of Medicine, UConn Health, The Jackson Laboratory for Genomic Medicine (JAX), and the Connecticut Agricultural Experiment Station. These institutions are at the forefront of discoveries in cancer treatment, regenerative medicine, gene editing, neuroscience, and infectious disease research. The Jackson Laboratory in Farmington, a world leader in genetics and genomics research, is pioneering precision medicine and contributing to groundbreaking advancements in personalized healthcare. Yale’s Center for Biomedical Innovation and Technology (CBIT) fosters collaboration between engineers, clinicians, and entrepreneurs to accelerate medical device and digital health innovations. Strategic Industry Partnerships Connecticut fosters strong public-private partnerships that drive innovation, economic growth, and commercialization of groundbreaking research. Organizations like BioCT, AdvanceCT, and the Connecticut Bioscience Growth Council work closely with industry leaders, startups, and research institutions to create an interconnected ecosystem that supports biotech investment and expansion. Connecticut Innovations, the state’s venture capital arm, provides funding and resources for early-stage biotech and medtech companies. Programs such as the Bioscience Innovation Fund and Angel Investor Tax Credit Program further enhance Connecticut’s competitive edge by attracting capital and talent to the state’s life sciences sector. State-of-the-Art Infrastructure & Incubators Connecticut’s bioscience industry thrives within a network of cutting-edge research facilities, technology incubators, and innovation hubs. The state has invested heavily in bioscience infrastructure, creating state-of-the-art lab spaces, research parks, and collaborative workspaces to support industry growth. The Connecticut Bioscience Innovation Network includes key sites such as: UConn Technology Incubation Program (TIP): With locations in Farmington and Stamford, TIP provides high-tech lab spaces and resources for startups in biotechnology, pharmaceuticals, and medical devices. BioCT Innovation Commons: A state-of-the-art incubator and co-working space in Groton that supports biotech entrepreneurs with wet lab space, mentorship, and commercialization assistance. Yale West Campus: A 136-acre research and technology hub that fosters collaboration between academia and industry to accelerate life sciences innovation. The Innovation Partnership Building (IPB): Located at UConn’s Tech Park, the IPB supports cutting-edge R&D in materials science, biomedical engineering, and precision medicine. Workforce & Talent Development Connecticut has one of the most educated workforces in the nation, ranking among the top states for STEM talent. The state’s commitment to workforce development ensures a steady pipeline of highly skilled professionals trained in bioscience, bioinformatics, computational biology, and biomedical engineering. Higher education institutions such as Yale, UConn, Quinnipiac University, and Wesleyan University offer specialized degree programs in biotechnology, pharmaceutical sciences, and biomedical research. The state also collaborates with industry leaders to design workforce training programs, including the Connecticut Health & Life Sciences Career Initiative, which equips students with the skills needed to excel in biotech and healthcare innovation. Advancements in Biopharma & Drug Development Connecticut’s strong foundation in pharmaceutical and biopharmaceutical research makes it a hub for drug discovery, development, and manufacturing. The state is home to some of the world’s leading pharmaceutical firms, including Pfizer, which operates one of its largest R&D facilities in Groton, where some of the most transformative drugs in history have been developed. With advancements in biologics, cell and gene therapies, and small molecule therapeutics, Connecticut-based companies are revolutionizing the treatment of rare diseases, cancer, and neurological disorders. The presence of top-tier contract research organizations (CROs) and contract development and manufacturing organizations (CDMOs) further strengthens Connecticut’s capabilities in pharmaceutical innovation. Medical Devices & Digital Health Leadership The state has a rich history of medical device innovation, with companies like Medtronic, Becton Dickinson (BD), and SCA Pharma leading the way in developing advanced surgical instruments, diagnostics, and healthcare technologies. Connecticut’s medtech sector is bolstered by research in biomedical engineering at Yale and UConn, as well as collaboration with hospitals and healthcare systems to improve patient outcomes. Digital health is another rapidly growing sector in Connecticut, driven by the state’s strengths in artificial intelligence, data analytics, and health informatics. Companies are leveraging AI-powered diagnostics, telemedicine, and wearable health technologies to enhance patient care and revolutionize healthcare delivery. Supportive Business Environment & Incentives Connecticut offers a highly supportive business climate for bioscience companies, with strategic incentives designed to foster growth, innovation, and global competitiveness. The state provides access to: Bioscience Innovation Fund: Grants and equity investments for bioscience startups and research initiatives. R&D Tax Credits: A robust tax credit program supporting research and development activities. Angel Investor Tax Credit: Encouraging private investment in early-stage bioscience ventures. Brownfield Remediation Program: Supporting site development for biotech companies looking to expand operations. Global Connectivity & Market Access Located in the heart of the Northeast biotech corridor, Connecticut provides seamless access to major markets, investors, and research institutions in Boston, New York City, and beyond. The state’s well-developed transportation infrastructure, including Bradley International Airport and proximity to major highways and rail lines, ensures efficient connectivity for business operations and global trade. Connecticut: The Future of Bioscience Innovation With a rich history of scientific discovery, a thriving network of biotech companies, world-renowned research institutions, and a highly skilled workforce, Connecticut is shaping the future of life sciences and healthcare innovation. Whether you’re a startup looking to scale, a multinational firm seeking cutting-edge R&D opportunities, or an investor exploring the next breakthrough technology, Connecticut offers the ideal environment to thrive in bioscience, life sciences, and biotechnology. Join us in Connecticut and be part of a dynamic ecosystem that is driving the next generation of scientific advancements and transforming healthcare worldwide.
City of Hope
City of Hope’s mission is to make hope a reality for all touched by cancer and diabetes. Founded in 1913, City of Hope has grown into one of the largest and most advanced cancer research and treatment organizations in the U.S., and one of the leading research centers for diabetes and other life-threatening illnesses. City of Hope research has been the basis for numerous breakthrough cancer medicines, as well as human synthetic insulin and monoclonal antibodies. With an independent, National Cancer Institute-designated comprehensive cancer center that is ranked top 5 in the nation for cancer care by U.S. News & World Report at its core, City of Hope’s uniquely integrated model spans cancer care, research and development, academics and training, and a broad philanthropy program that powers its work. City of Hope’s growing national system includes its Los Angeles campus, a network of clinical care locations across Southern California, a new cancer center in Orange County, California, and cancer treatment centers and outpatient facilities in the Atlanta, Chicago and Phoenix areas. City of Hope’s affiliated group of organizations includes Translational Genomics Research Institute and AccessHopeTM. For more information about City of Hope, follow us on Facebook, X, YouTube, Instagram and LinkedIn. | City of Hope’s mission is to deliver the cures of tomorrow to the people who need them today. Founded in 1913, City of Hope has grown into one of the largest cancer research and treatment organizations in the U.S. and one of the leading research centers for diabetes and other life-threatening illnesses. City of Hope research has been the basis for numerous breakthrough cancer medicines, as well as human synthetic insulin and monoclonal antibodies. With an independent, National Cancer Institute-designated comprehensive cancer center at its core, City of Hope brings a uniquely integrated model to patients spanning cancer care, research and development, academics and training, and innovation initiatives. City of Hope’s growing national system includes its Los Angeles campus, a network of clinical care locations across Southern California, a new cancer center in Orange County, California, and treatment facilities in Atlanta, Chicago and Phoenix. City of Hope’s affiliated group of organizations includes Translational Genomics Research Institute and AccessHopeTM. For more information about City of Hope, follow us on Facebook, Twitter, YouTube, Instagram and LinkedIn. | City of Hope’s mission is to make hope a reality for all touched by cancer and diabetes. Founded in 1913, City of Hope has grown into one of the largest cancer research and treatment organizations in the U.S. and one of the leading research centers for diabetes and other life-threatening illnesses. City of Hope research has been the basis for numerous breakthrough cancer medicines, as well as human synthetic insulin and monoclonal antibodies. With an independent, National Cancer Institute-designated comprehensive cancer center at its core, City of Hope brings a uniquely integrated model to patients spanning cancer care, research and development, academics and training, and innovation initiatives. City of Hope’s growing national system includes its Los Angeles campus, a network of clinical care locations across Southern California, a new cancer center in Orange County, California, and cancer treatment centers and outpatient facilities in the Atlanta, Chicago and Phoenix areas. City of Hope’s affiliated group of organizations includes Translational Genomics Research Institute and AccessHopeTM. For more information about City of Hope, follow us on Facebook, X, YouTube, Instagram and LinkedIn. | City of Hope is a world leader in cancer research, treatment and care. Since 1913, we have been dedicated to making a meaningful impact in the fight against life-threatening illnesses. Accordint o U.S. News and World Report, City of Hope is a top 5 cancer center in the United States and #1 in California. City of Hope’s Charitable Remainder Trust (CRT) program enables agricultural property owners to bypass capital gains tax when selling appreciated property. Additional benefits include creating a new source of lifetime income for the property owner and/or loved ones, a charitable income tax deduction and is a viable succession plan option for those who would like to downsize or retire from the property ownership business. In accordance with the IRS Code, a Charitable Remainder Trust (CRT) is a separate legal and charitable entity. When transferring property into a CRT first, the trust can sell the donated property and bypass capital gains tax at the time of the sale. After the donor’s lifetime, City of Hope will have access to the remaining funds for use towards research, making a difference in the lives of people with cancer, diabetes and other life-threatening illnesses.
Cincinnati Children’s Innovation Ventures
Cincinnati Children’s is a nationally ranked pediatric health system and a recognized leader in both pediatric and adult research. With a legacy of impact spanning more than 90 years—from Albert Sabin’s oral polio vaccine to pioneering discoveries in lung surfactant proteins—we continue to advance science that improves lives. As one of the largest pediatric research institutions in the U.S., we secure $300 million in external research funding annually and play a central role in shaping the future of biomedical innovation. Innovation is embedded in our culture. One-third of our 19,000 employees are engaged in research and innovation across a broad spectrum of life sciences. From breakthrough therapeutic candidates and biotech platforms to diagnostics, medical devices, software, and research tools, our teams are building a pipeline of technologies with the potential for real-world impact. Explore our innovation portfolio and partnership opportunities at cincinnatichildrens.org/innovation-ventures.
BioUtah
BioUtah is an independent, non-profit 501(c)(6) trade association serving the life sciences community in the state of Utah. We are comprised of manufacturers and developers of medical devices, pharmaceuticals, diagnostics and biotechnology products as well as government, academic and health care institutions all focused on improving health and wellness through the delivery of innovative technologies and services. We also count among our members those who support our industry such as national trade associations and key service providers. Together we create a community that fosters collaboration, promotes innovation, and accelerates health care advances to save lives and improve the quality of life. We are passionately focused on advancing and growing Utah’s life sciences industry by assuring legislative initiatives at both the state and federal level are calculated to advance the cause of health care in Utah, burnishing the image of our industry in both the public and private sectors helping them to better appreciate the economic contributions made by our industry, providing educational forums for industry in order to bring current topics of discussion to the forefront, and encouraging collaboration and innovation amongst our members. Utah’s life sciences industry is a key driver of the state’s economy. BioUtah is committed to growing Utah into a global life sciences leader, a recognized epicenter for innovation, health care quality, and job creation. A recent study conducted by the state of Utah revealed that from 2012 to 2022 Utah’s life sciences industry was one of the three fastest growing of all life science clusters in the United States. | x | BioUtah is an independent, non-profit 501(c)(6) trade association serving the life sciences community in the state of Utah. We are comprised of manufacturers and developers of medical devices, pharmaceuticals, diagnostics and biotechnology products as well as government, academic and health care institutions all focused on improving health and wellness through the delivery of innovative technologies and services. We also count among our members those who support our industry such as national trade associations and key service providers. Together we create a community that fosters collaboration, promotes innovation, and accelerates health care advances to save lives and improve the quality of life. We are passionately focused on advancing and growing Utah’s life sciences industry by assuring legislative initiatives at both the state and federal level are calculated to advance the cause of health care in Utah, burnishing the image of our industry in both the public and private sectors helping them to better appreciate the economic contributions made by our industry, providing educational forums for industry in order to bring current topics of discussion to the forefront, and encouraging collaboration and innovation amongst our members. Utah’s life sciences industry is a key driver of the state’s economy. BioUtah is committed to growing Utah into a global life sciences leader, a recognized epicenter for innovation, health care quality, and job creation. We work closely with government and industry to foster economic development and attract companies to Utah. A recent study conducted by the Kem C. Gardner Policy Institute at the University of Utah revealed that from 2012 to 2022 Utah’s life sciences industry was the third fastest growing of all life science clusters in the United States.
BIOTECHNOLOGY VALLEY
The Biotechnology Industrialists’ Association (BİYOSAD) aims to drive human development via innovative, high value-added products and services and is establishing the Biotechnology Valley within the Biotechnology Specialized Industrial Zone (BİOSB) in Istanbul. This project aspires to situate Turkey among the world’s leading biotechnology hubs. Biotechnology Valley, positioned in strategically located Tuzla, Istanbul, is a comprehensive initiative designed to create a specialized biotechnology ecosystem. The project aims to boost Turkey’s global presence in the biotechnology market through strong collaborations between business, academia, and the government. It spans 2.7 million square meters and will feature technology development zones, R&D centers, testing and calibration labs, patent offices, and specialized biotechnology schools. Our goal is to enhance global export potential by fostering domestic production of high value-added biotechnology products. We prioritize guiding industry and academia toward innovative collaboration, exploring nature’s possibilities in light of science. Our mission extends beyond meeting current demands to making a positive impact for future generations through sustainable and collaborative efforts. Biotechnology Valley is dedicated to enabling breakthrough technologies in the sector and hosting research that benefits society, adding value to both science and business. We are committed to providing a safe, innovative, and supportive business environment for all sector stakeholders. Join us as a partner in transforming Türkiye and the world into a leading biotechnology center. | Biotechnology Valley is a strategic technology and innovation ecosystem established under the leadership of the Biotechnology Industrialists Association (BIYOSAD) to lead Türkiye’s vision in biotechnology across science, technology, and production. Bringing together the public sector, industry, academia, and investors, the Valley aims to build a high–value-added, sustainable, and globally competitive biotechnology infrastructure. Located in Tepeören, Istanbul, and spanning approximately 2.7 million square meters, Biotechnology Valley is one of Türkiye’s most comprehensive biotechnology initiatives. With its advanced R&D centers, technology development zones, modern manufacturing facilities, and shared infrastructure, the Valley is designed as an integrated hub for local and international companies operating in pharmaceuticals, biotechnology products, medical technologies, and advanced life sciences. Biotechnology Valley is not only a center for production and R&D, but also a living and innovation ecosystem with sustainability at its core. The project prioritizes energy-efficient infrastructure, renewable energy solutions, water efficiency practices, integrated waste management systems, and comprehensive strategies to reduce carbon footprint. This approach positions biotechnology production in harmony with nature and with a strong sense of responsibility toward future generations. The Valley offers a collaborative, innovative, and scalable ecosystem for a wide range of stakeholders, from start-ups and research institutions to global players and investment funds. Through its open innovation approach, Biotechnology Valley promotes knowledge sharing and co-creation, aiming to integrate Türkiye’s biotechnology potential into the global value chain. With its robust infrastructure, sustainability-driven framework, and international vision, Biotechnology Valley continues to advance with determination toward becoming a regional and global center for biotechnology.
BIO3S Co., Ltd
BIO3S Co., Ltd. is a biotechnology company specializing in antiviral solutions and specimen collection systems. With proprietary plant-derived virus-binding technologies, BIO3S develops products that ensure safe hygiene and accurate diagnostics, including the NORO-X Foaming Hand Soap and OralMax® Oral Specimen Collection Kit. BIO3S is a trusted supplier to public institutions and is expanding into digital healthcare. Virus-Binding Protein Technology for Hygiene and Diagnostics – BIO3S’s Dual Application in Hand Hygiene and Oral Diagnostics At the heart of BIO3S’s innovation lies its proprietary virus-binding lectin protein, extracted from sword beans (Canavalia gladiate), which demonstrates strong affinity for viral surface proteins. This powerful natural compound serves as the foundation for two of BIO3S’s flagship products: the NORO-X Foaming Hand Soap and the OralMax® Oral Specimen Collection Kit—each tailored to a different phase of viral control, from prevention to detection.
Andelyn Biosciences
Our Vision: Pioneering Solutions that turn Hope into Reality Our Mission: Accelerating the development and manufacturing of innovative therapies to bring more treatments to more patients Andelyn Biosciences (https://www.andelynbio.com/) is pioneering solutions that turn hope into reality as a cell and gene therapy CDMO. Capabilities span viral vector process and analytical development, small to large scale adherent and suspension based GMP manufacturing up to 2000L. Having 20+ years of experience with viral vector manufacturing, Andelyn offers access to globally recognized thought leaders with troubleshooting/characterization expertise and GMP material produced for 75+ worldwide clinical trials. In addition to producing 400+ cGMP clinical batches, Andelyn provides research and tox grade plasmids with an additional offering of GMP plasmid manufacturing, full quality system/regulatory support and supply chain vertical integration. Its state-of-the-art 185,000 sq ft commercial manufacturing facility will expand capacity across 8+ production suites for customization of new programs and tech transferred programs, offering clinical through commercial-scale capabilities that will help accelerate innovative therapies to bring more treatments to more patients. Gene and cell therapy, AAV viral vector manufacturing, Plasmid Manufacturing, Lentiviral vector Manufacturing, Commercial Manufacturing, CDMO, analytical method development, GMP, fill finish, QC/QA release testing, Process Characterization, Regulatory Affairs, Licensing Andelyn Biosciences is a pioneering cell and gene therapy organization born out of Nationwide Children’s Hospital, where the first FDA-approved systemic gene therapy was discovered. See all our Press Releases at: https://www.andelynbio.com/media-center | Andelyn Biosciences (https://www.andelynbio.com/) is pioneering solutions for Turning Hope into Reality (TM) as a gene therapy CDMO. Capabilities span viral vector process and analytical development, small to large scale adherent and suspension based GMP manufacturing up to 2000L. With 20+ years of experience in viral vector manufacturing, Andelyn offers access to globally recognized thought leaders with troubleshooting and characterization expertise and GMP material produced for 75+ worldwide clinical trials. In addition to producing 450+ cGMP sublots, Andelyn provides research, tox, and GMP grade plasmids Andelyn also has full quality and regulatory support and supply chain vertical integration. Its state-of-the-art 185,000 sq ft commercial manufacturing facility offers capacity across 16 production suites for customization of new programs as well as tech transfer programs, offering clinical through commercial-scale capabilities that will help accelerate innovative therapies to bring more treatments to more patients. Andelyn Biosciences is a pioneering gene therapy CDMO born out of Nationwide Children’s Hospital, where the first FDA-approved systemic gene therapy was discovered. | Andelyn Biosciences is a full-service cell and gene therapy CDMO focused on the development, characterization and production of viral vectors for gene therapy. With more than 20 years of experience, Andelyn’s deep scientific expertise has resulted in the production of cGMP material for more than 450 clinical batches and 75 global clinical trials. Operating out of its development and manufacturing facilities in Columbus, Ohio, Andelyn supports its clients in developing cell and gene therapies from concept through plasmid engineering and manufacturing, process and analytical development, and cGMP clinical and commercial manufacturing. Andelyn can accelerate programs and deliver high quality products by developing and manufacturing processes on its configurable, data-driven AAV CuratorTM Platform, or tech transferring in an established client program. Capabilities include cGMP manufacturing for suspension processes up to a 2,000-liter and adherent processes. A rigorous quality system, regulatory support, and supply chain vertical integration further support clients in bringing their critical therapies to market. For more information, visit andelynbio.com. For Andelyn media inquiries, please contact: media@andelynbiosciences.com